LARIMAR THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
LARIMAR THERAPEUTICS, INC. (LRMR) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $2.15 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-04
- LARIMAR THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $2.15M, a 17.56% increase year-over-year.
- LARIMAR THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.98M, a 7.91% increase year-over-year.
- LARIMAR THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $1.78M, a 8.79% decline year-over-year.
- LARIMAR THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $1.83M, a 20.56% decline year-over-year.
- LARIMAR THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $7.00M, a 20.37% decline from fiscal 2024.
- LARIMAR THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $8.80M, a 15.51% increase from fiscal 2023.
- LARIMAR THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $7.62M, a 15.05% increase from fiscal 2022.
- LARIMAR THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $6.62M, a 20.94% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2.15M 10-Q · filed 2026-08-04 | $4.13M derived: sum of 2 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $1.98M 10-Q · filed 2026-08-04 | |||||
| 2025-12-31 | $7.00M 10-K · filed 2026-03-19 | |||||
| 2025-09-30 | $1.78M 10-Q · filed 2025-11-05 | $3.61M derived: sum of 2 quarters · filed 2026-08-04 | $5.45M derived: sum of 3 quarters · filed 2026-08-04 | |||
| 2025-06-30 | $1.83M 10-Q · filed 2026-08-04 | $3.66M derived: sum of 2 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $1.83M 10-Q · filed 2026-08-04 | |||||
| 2024-12-31 | $8.80M 10-K · filed 2026-03-19 | |||||
| 2024-09-30 | $1.96M 10-Q · filed 2025-11-05 | $4.26M derived: sum of 2 quarters · filed 2025-11-05 | $6.39M derived: sum of 3 quarters · filed 2025-11-05 | |||
| 2024-06-30 | $2.30M 10-Q · filed 2025-11-05 | $4.43M derived: sum of 2 quarters · filed 2025-11-05 | ||||
| 2024-03-31 | $2.13M 10-Q · filed 2025-11-05 | |||||
| 2023-12-31 | $7.62M 10-K · filed 2025-03-24 | |||||
| 2023-09-30 | $1.82M 10-Q · filed 2024-10-30 | $3.86M derived: sum of 2 quarters · filed 2024-10-30 | $5.70M derived: sum of 3 quarters · filed 2024-10-30 | |||
| 2023-06-30 | $2.04M 10-Q · filed 2024-10-30 | $3.88M derived: sum of 2 quarters · filed 2024-10-30 | ||||
| 2023-03-31 | $1.83M 10-Q · filed 2024-10-30 | |||||
| 2022-12-31 | $6.62M 10-K · filed 2024-03-14 | |||||
| 2022-09-30 | $1.67M 10-Q · filed 2023-11-14 | $3.34M derived: sum of 2 quarters · filed 2023-11-14 | $4.98M derived: sum of 3 quarters · filed 2023-11-14 | |||
| 2022-06-30 | $1.68M 10-Q · filed 2023-11-14 | $3.31M derived: sum of 2 quarters · filed 2023-11-14 | ||||
| 2022-03-31 | $1.64M 10-Q · filed 2023-11-14 | |||||
| 2021-12-31 | $5.47M 10-K · filed 2023-03-14 | |||||
| 2021-09-30 | $1.46M 10-Q · filed 2022-11-10 | $2.81M derived: sum of 2 quarters · filed 2022-11-10 | $3.99M derived: sum of 3 quarters · filed 2022-11-10 | |||
| 2021-06-30 | $1.35M 10-Q · filed 2022-11-10 | $2.53M derived: sum of 2 quarters · filed 2022-11-10 | ||||
| 2021-03-31 | $1.18M 10-Q · filed 2022-11-10 | |||||
| 2020-12-31 | $2.16M 10-K · filed 2022-03-25 | |||||
| 2020-09-30 | $370.00K 10-Q · filed 2021-11-12 | $1.12M derived: sum of 2 quarters · filed 2021-11-12 | $1.15M derived: sum of 3 quarters · filed 2021-11-12 | |||
| 2020-06-30 | $752.00K 10-Q · filed 2021-11-12 | $781.00K derived: sum of 2 quarters · filed 2021-11-12 | ||||
| 2020-03-31 | $29.00K 10-Q · filed 2021-11-12 | $710.00K 10-Q · filed 2020-05-07 | ||||
| 2019-12-31 | $129.00K 10-K · filed 2021-03-04 | $5.50M 10-K · filed 2020-03-05 | ||||
| 2019-09-30 | $33.00K 10-Q · filed 2020-11-12 | $604.00K 10-Q · filed 2019-11-06 | $66.00K derived: sum of 2 quarters · filed 2020-11-12 | $100.00K derived: sum of 3 quarters · filed 2020-11-12 | ||
| 2019-06-30 | $33.00K 10-Q · filed 2020-11-12 | $1.88M 10-Q · filed 2019-08-08 | $67.00K derived: sum of 2 quarters · filed 2020-11-12 | |||
| 2019-03-31 | $34.00K 10-Q · filed 2020-11-12 | $2.08M 10-Q · filed 2019-05-09 | ||||
| 2018-12-31 | $9.63M 10-K · filed 2020-03-05 | |||||
| 2018-09-30 | $2.20M 10-Q · filed 2019-11-06 | $4.87M derived: sum of 2 quarters · filed 2019-11-06 | $7.34M derived: sum of 3 quarters · filed 2019-11-06 | |||
| 2018-06-30 | $2.67M 10-Q · filed 2019-11-06 | $5.14M derived: sum of 2 quarters · filed 2019-11-06 | ||||
| 2018-03-31 | $2.47M 10-Q · filed 2019-11-06 | |||||
| 2017-12-31 | $8.30M 10-K · filed 2020-03-05 | |||||
| 2016-12-31 | $10.11M 10-K · filed 2019-03-14 | |||||
| 2015-12-31 | $8.58M 10-K · filed 2018-03-09 | |||||
| 2014-12-31 | $1.55M 10-K · filed 2017-03-10 | |||||
| 2013-12-31 | $395.00K 10-K · filed 2016-03-15 | |||||
| 2012-12-31 | $121.00K 10-K · filed 2015-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |